Pfizer Products Acquisition

Alliance Pharma PLC
06 July 2006


For Immediate Release                                              6 July 2006



                             ALLIANCE PHARMA PLC

                      ('Alliance Pharma' or 'the Company')

  Expansion of UK skincare portfolio through product acquisitions from Pfizer



Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is
pleased to announce that it is further expanding its dermatology portfolio
through the acquisition from Pfizer of the UK rights to three products: the oral
antihistamine AtaraxTM, the oral steroid DeltacortrilTM and TerracortrilTM, a
topical combination steroid.  Atarax and Deltacortril had combined annualised
sales of around £2.8 million in the UK in the 12 months to May 2006.


For each of the three brands, Alliance will transfer the manufacturing,
reformulate the products to improve their profitability and will then pay Pfizer
a consideration out of cashflow over the following three years.


Sales of Atarax, which is used increasingly to treat itchy skin disorders, are
growing steadily at 11% per annum.  The product will further strengthen
Alliance's dermatology portfolio, which has been built through the selective
acquisition of products and companies.


Deltacortril, is used for a wide range of steroid-responsive conditions such as
asthma, ulcerative colitis, rheumatoid arthritis and eczema.  It has a mature
sales profile and as such will fit well into Alliance's portfolio of unpromoted,
stable-selling products which deliver the cashflow to fund the Company's
development pipeline.


Alliance plans to relaunch Terracortril which has been off the UK market for
some 18 months. The product is used by specialised burns units and its return
has been canvassed by clinicians.


John Dawson, Alliance Pharma's Chief Executive, commented:

'We are very pleased Pfizer selected Alliance as its partner to help rationalise
their portfolio. These are important medicines and we are pleased to be able to
ensure their continued availability via our process of manufacturing
optimisation. Our dermatology portfolio has been a key area of focus for
Alliance during the past year so I am delighted by this acquisition of three
important brands to expand our franchise. In addition to treating skin
conditions two of these three products treat other indications and we look
forward also to serving those treatment areas.'


Carl Davis, Head of Business Development for Pfizer Limited, said:

'Pfizer has a commitment to partnering with organisations to deliver healthcare
benefits. We are very pleased to partner with Alliance on Atarax, Deltacortril
and Terracortril as their strategic focus will ensure a wide range of patients
will continue to benefit from these medicines.  As the world's leading
pharmaceutical company, we are happy to support an emerging British company.'



For further information:


Alliance Pharma plc                                         + 44 (0) 1249 466966

John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications                                    + 44 (0) 20 7466 5000

Mark Court/ Rebecca Skye Dietrich/Lisa Baderoon

Pfizer Press Office                                         + 44 (0) 1737 332332
Lisa O'Neill




Notes to editors



About Alliance Pharma


Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 32 branded pharmaceutical products and continues to explore
opportunities to expand the range.



 Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven.  Its products are
distributed to hospitals directly and to UK and International pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.


Alliance Pharma is also developing Posidorm(R) for sleep disorders and Isprelor
(R) for the induction of labour.


Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.



About Pfizer

Pfizer, with its UK business headquarters in Surrey and global headquarters in
New York, is a research-based global pharmaceutical company. Pfizer discovers,
develops, manufactures and markets leading prescription medicines for humans and
animals, and many of the world's best-known consumer treatments. Every month,
over two million patients in the UK are prescribed a Pfizer medicine. It is
estimated that on any given day, 40 million people around the world are treated
with a Pfizer medicine.






                      This information is provided by RNS
            The company news service from the London Stock Exchange